The EMA authorizes the third dose of Moderna’s vaccine for people over 18 years of age

The European Medicines Agency (EMA) has given the green light to the application to the general adult population of a booster dose of the COVID-19 vaccine of Moderna between six to eight months after the second injection.

The European regulator reviewed data presented by the American pharmaceutical company that shows that a third dose of this preparation, six to eight months after the second, “caused an increase in adult antibody levels” in those who had decreased over time.

Positive results in children 6 to 12 years

Modern pharmaceutical company has also announced that its vaccine against COVID-19 has shown promising results for children in the range of 6 to 12 years, by demonstrating a “Robust antibody neutralization response”.

In a statement, the company states that its 50-microgram, double-dose vaccine, called “KidCOVE” was administered to 4,753 participants in chemical trials, which mostly reacted positively, with mild side effects such as fatigue, headache, or pain at the site of the puncture.

All participants will have their status monitored by Moderna for twelve months from the second puncture to control your level of protection and security, which could lead to changes in the data collected so far.

The company will present these results to the United States Food and Drug Administration (FDA, regulatory agency) and to the European Medicines Agency for eventual approval, as the idea of ​​vaccinating children makes its way in many countries.

Also, Modern continues to research for a possible vaccine for younger children, ages 6 months to 6 years, and has already enrolled 5,700 participants in the United States and Canada, a study that is being prepared in collaboration with the National Institute of Health (NIH) and the government Department of Health. On October 7, Pfizer and BioNtech applied to the FDA for authorization for the emergency use of their vaccine against COVID-19 in children 5 to 11 years old, and Pfizer published last week that its vaccine has shown effectiveness in 90% of cases.